![]() |
A Close Concurrence on Certolizumab (Cimzia®)...
September 1, 2013 - Clinical , Featured By: Sang Hyo Kim, Staff Editor – This year, on July 23rd, FDA advisers voted 7 to 6, with one abstention, in favor of approving the drug certolizumab (Cimzia®) for the indication of axial spondyloarthritis (axSpA). axSpA is a chronic imflammatory condition that includes ankylosing spondylitis (AS) and non-radiographic axial spndyloarthristis (nr-axSpA).1,2 axSpA, AS and… |
![]() |
New Findings Regarding Cardiovascular Adverse Events wi...
August 1, 2013 - Clinical , Featured By: Aleena Cherian, Co-Copy Editor [Graphics-Focused] – Attention deficit/hyperactivity disorder (ADHD) is a chronic neurological behavior characterized by persistent patterns of inattention and/or hyperactive behavior, resulting in a wide range of emotional, functional, and neurocognitive impairments.1,2 First line therapy for ADHD consists of stimulant medications together with non-pharmacologic interventions, and has been shown to improve… |
![]() |
DIA 2013 Annual Meeting: Boston, Massachusetts...
August 1, 2013 - Events By: Kristin M. Cheng, PharmD candidate c/o 2014 – The Drug Information Association (DIA) 2013 Annual Meeting took place from June 23rd to June 27th at the Boston Convention and Exhibition Center in Boston, Massachusetts. Twenty-one students from the St. John’s University DIA student chapter attended this year. The purpose of the meeting was… |
![]() |
Solving the HCV Enigma: Current and Future Drug Therapy...
July 1, 2013 - Clinical , Featured By: Tamara Yunusova, Senior Staff Editor – Approximately 3.2 million Americans have chronic hepatitis C infection.1 While acute cases are not common, rates of chronic hepatitis C continue to surge due to the recent discovery of the virus in 1989 and consequently, the establishment of a test screening for HCV antibodies in 1992.1 HCV has… |
![]() |
Compounding at a Crossroads: New Boundaries in the Afte...
July 1, 2013 - Featured , In the News / Politics Davidta Brown, PharmD Candidate c/o 2017 – The debate on the nature of compounding practice and the extent to which it ought to be regulated has come to the forefront of public attention. Those who regularly follow American news and politics are familiar with the series of events that have led to the present… |
![]() |
FDA Takes Major Strides Towards Opioid Abuse Prevention...
June 1, 2013 - Featured , In the News / Politics By: Ada Seldin PharmD Candidate c/o 2015 – On April 16th, 2013, the FDA approved the labeling change for the reformulated OxyContin® (oxycodone hydrochloride controlled-release) tablets, made by Pharma L.P. This change reflects the abuse-deterrent properties of the reformulated OxyContin®, which were not present in the original formulation approved by the FDA in 1995. OxyContin®… |
![]() |
Helping Solve the Cruel Mystery...
June 1, 2013 - Featured , In the News / Politics By: Erica Dimitropoulos, Senior Staff Editor – Lupus is highly unpredictable and occurs without warning; there is no known cause and no known cure. It affects over 1.5 million Americans, 90% of whom are women between the ages of 15 – 44.1 No two cases of lupus are alike, making it a very difficult disease… |
![]() |
Pay to Delay: The Honest Truth...
June 1, 2013 - Professional Advice / Opinions By: David Ong, Pharm.D. Candidate c/o 2014 – Our current healthcare system receives much criticism from the press as well as the public. Big pharmaceutical companies (“Big Pharma”) have consistently been characterized as part of the problem. Most of the blame for high drug costs is levied on Big Pharma. One of the criticisms is… |
![]() |
FDA Approves Dimethyl Fumarate for Treatment of Relapsi...
June 1, 2013 - Clinical , Featured By: Andy Zhang, PharmD Candidate c/o 2015 – On March 28, 2013, the U.S. Food and Drug Administration announced the approval of Tecfidera™ (dimethyl fumarate) for the treatment of relapsing forms of multiple sclerosis (MS) in adults.1 Tecfidera™ (dimethyl fumarate) will be the third oral drug used for the treatment of MS. The manufacturer Biogen… |
![]() |
Noninvasive Cancer Screening—Will We Ever Get It Righ...
June 1, 2013 - Clinical , Featured By: Frances Sousonis, Candidate c/o 2017 – Unfortunately, cancer is a disease about which many are able to share stories. All too often, beloved persons are diagnosed with cancer, or, more regrettably, loses their battle with the beast. Colon cancer is the third most common cancer in the United States and around 150,000 people each… |
![]() |
Regulation of Low to Moderate Risk Medical Devices by t...
May 1, 2013 - Featured , Professional Advice / Opinions By: Hayeon Na, Co-Copy Editor [Content-Focused] – On March 22, 2013, Public Broadcasting Service (PBS) aired an episode of “Need to Know” on the safety of low to moderate risk medical devices. The episode closely followed the lawsuit of patient Linda Gross who has pelvic organ prolapse and was advised by her doctor to undergo… |
![]() |
Can a Pharmacist Prevent the Next Pileup?...
May 1, 2013 - Clinical By: Moisey Rafailov, PharmD Candidate c/o 2015 – It was early in the morning on New York’s Route 684 when a car hit a tractor-trailer and continued driving without regard. Imagine that, when later stopped by a police officer, the driver said that the accident was her pharmacist’s fault. What if I were to tell… |
![]() |
Plan B® Pill Now Available Without Prescription to Wom...
May 1, 2013 - Featured , In the News / Politics By: Bansri Patel – As of May 1st 2013, Plan B®, the brand name emergency contraception pill will now be available to women aged fifteen and older. It will also be sold in the drug store aisles, as opposed to its current location behind the pharmacy counter. When levonorgestrel (Plan B®) first entered the market,… |
![]() |
FDA Approves New Drug ‘Tofacitinib’ for Rheumatoid ...
April 1, 2013 - Clinical , Featured By: Erica Dimitropoulos, Senior Staff Editor – Rheumatoid arthritis is a painful and often debilitating autoimmune disease characterized by symmetric polyarthritis, most commonly of the proximal interphalangeal and metacarpophalangeal joints, elbows, knees, ankles, and spine.1 Its clinical manifestations vary, from a slowly progressing onset of fatigue and musculoskeletal discomfort to a sudden and worsening destruction… |
![]() |
Flu Season 2012-2013: Rising Opportunities for Pharmaci...
April 1, 2013 - Clinical By: Fawad Piracha, Pharm. D Candidate c/o 2016 – The 2012-2013 influenza season has developed into one of the greatest nationwide flu outbreaksof the decade.1 Amid this crisis, many flocked to healthcare providers with flu-like symptoms, while others scoured doctors’ offices, clinics, and pharmacies for the vaccine. With the flu claiming many lives throughout the… |
![]() |
New P2Y12 Antagonist on the Rise...
April 1, 2013 - Clinical By Nancy Rizkalla, PharmD candidate c/o 2015 – Percutaneous coronary intervention (PCI) with subsequent stent implantation is a highly effective approach in reducing the risk of death or ischemic complications following a myocardial infarction as well as improving the quality of life in patients with stable angina. PCI is ultimately performed in 60 –… |
![]() |
U.S. v Caronia: Misdemeanor or Constitutional Right?...
March 1, 2013 - Featured , In the News / Politics By: Tamara Yunusova, Staff Editor – On December 3, 2012, the U.S. Second Circuit Court of Appeals became the first court in the nation to authorize off-label drug promotion under the First Amendment. The heavily-disputed ruling, which is headed for further appeal, will have far-reaching implications for pharmaceutical companies and drug regulation policy. In a… |
![]() |
New FDA Approval: Fycompa® to Treat Seizures...
March 1, 2013 - Clinical , Featured By: Bhavini Shah, PharmD Candidate c/o 2013 – Fycompa® (perampanel) has received the U.S. Food and Drug Administration (FDA) approval for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.1 The drug, manufactured by Eisai Inc., is already approved for use in Iceland,… |
![]() |
FDA Approves New Indication for Botox (Onabotulinumtoxi...
March 1, 2013 - Clinical , Featured By: Bethsy Jacob, PharmD Candidate 2014 – On January 18, 2013, the U.S. Food and Drug Administration (FDA) announced a new approval for Botox, generically known as OnabotulinumtoxinA. Patients diagnosed with urinary incontinence due to an overactive bladder can be prescribed Botox, if they are unable to take or are unresponsive to anticholinergic medications. This… |
![]() |
Rho Chi Beta Delta Chapter Induction Ceremony...
February 1, 2013 - Events By: Bethsy Jacob, PharmD Candidate c/o 2013 – On January 24, 2013, Rho Chi Beta Delta Chapter successfully conducted its annual induction ceremony, welcoming forty-four new members into the chapter. Membership was granted to students who ranked in the top 20% of their class. This year’s inductees included 4th and 5th year PharmD students as… |
![]() |
Emerging Pathways For Treating Hepatitis C Virus...
February 1, 2013 - Clinical , Featured By: Maria Sorbera, PharmD Candidate c/o 2013, AMSCOP, LIU – Hepatitis C is the leading cause of chronic liver disease and cirrhosis, presenting a global health challenge. Approximately 170 million people worldwide, 3% of the population, are infected with the Hepatitis C Virus (HCV), roughly 3.2 million of whom reside in the United States. The… |
![]() |
Varizig® for Chickenpox Symptoms...
January 1, 2013 - In the News / Politics By: Steve Soman, Co-Editor-in-Chief – Varicella Zoster Immune Globulin (Varizig®) was approved by the FDA on December 21st of 2012. The Canadian pharmaceutical company Cangene Corporation, which is owned in-part by Apotex Inc., markets the new product. The drug was approved by the Food and Drug Administration (FDA) to reduce “the severity of chicken pox… |
![]() |
The Opioid Debate: PROP and PROMPT Battle Away...
January 1, 2013 - Featured , In the News / Politics By: Tamara Yunusova – On Wednesday, July 25th a petition signed by the reform group Physicians for Responsible Opioid Prescribing (PROP) called on the FDA to implement opioid label changes that would restrict Chronic Non-Cancer (CNCP) opioid treatment for patients with severe pain only. It wasn’t too long before another petition signed by PROP’s adversary,… |
![]() |
New Healthcare Law Concerning Birth Control Causes Deba...
January 1, 2013 - Featured , In the News / Politics By: Katie Cimmino, Pharm D. Candidate c/o 2015 – With the start of the New Year the French government is enacting a new law concerning contraceptives. Now girls between the ages of 15 to 18 will be able to obtain free birth control. Not only will they have access to it, but the French government… |
![]() |
FDA Approves Apixaban For Nonvalvular Atrial Fibrillati...
January 1, 2013 - Clinical , Featured , In the News / Politics By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1 This occurred one month after its approval in Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is… |
![]() |
Tackling America’s Drug Shortage Crisis...
December 1, 2012 - Featured , In the News / Politics , Professional Advice / Opinions By: John S Lim, PharmD Candidate c/o 2013 – America’s focus on healthcare, as well as its position as one of the wealthiest nations of the industrialized world, is incongruous with the consequences of drug shortages suffered by its population. Shortages in pharmaceutical supply compromise quality of life while increasing health care costs. The pharmaceutical… |
![]() |
Adverse Events from Ingestion of OTC Eye Drops and Nasa...
December 1, 2012 - Featured , In the News / Politics By Tasnima Nabi, PharmD Candidate c/o 2016 – The FDA has issued warnings on accidental ingestion of over-the-counter eye drops and nasal sprays because they can cause serious harm in children at and under the age of five. Ingestion of as little as 0.6 ml of OTC nasal decongestants and redness-relief eye drops has been… |
![]() |
Fungal Meningitis Outbreak: A Sobering Tragedy...
November 1, 2012 - In the News / Politics By: Mahdieh Danesh Yazdi, Associate Student Editor – For the past few weeks, we have heard about the terrible breakout of fungal meningitis from contaminated methylprednisolone acetate vials manufactured by the New England Compounding Center (NECC). Approximately 14,000 patients received medication from the contaminated lots. So far, over 400 cases have been reported and over… |
![]() |
New Drug Review: Tofacitinib (Xeljanz®)...
November 1, 2012 - Clinical By: Jessica Lee, PharmD Candidate c/o 2013 – Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks healthy tissue, causing inflammation of the joints and potential harm to other organs.1 It affects 0.5-1% of the adult population and is more prevalent in the seventh decade of life.1 These patients tend to… |
![]() |
A New Frontier in Health Care: Digital Medicine...
October 1, 2012 - Professional Advice / Opinions By: Mahdieh Danesh Yazdi – We live in amazing times. Technology does not progress by steps anymore, it grows by leaps. Health-care has reaped the benefits of these advances just like any other industry. It was not a very long time ago that pharmacists would look up patient records in a book full of names… |
![]() |
Influenza Vaccines: Projected Strains for the 2012—20...
September 1, 2012 - Clinical , Featured By: Joo Hee Kwon, Pharm.D. Candidate c/o 2013 – There are 3 antigenic types of influenza: A, B, and C. Influenza C causes mild illness and therefore does not cause epidemics. In contrast, influenza A and B are capable of causing mild to severe flu and in some cases death. An epidemic can occur depending… |
![]() |
Bisphosphonates and Atypical Fracture Risk...
September 1, 2012 - Clinical , Featured By: Steve Soman, Pharm.D. Candidate c/o 2013 – Bisphosphonates are proven to enhance bone density and reduce fracture incidence in post-menopausal women but recent data suggests they may have adverse effects with regards to bone quality. The drugs in this class can be differentiated as non-nitrogen containing (older generation) and nitrogen containing (newer generation) medications.… |
![]() |
Brand Vs. Generic: What Every Prescriber Should Know...
September 1, 2012 - Clinical , Featured , Professional Advice / Opinions By: Marina Yermolayeva, PharmD Candidate c/o 2013 – “I’m allergic to the generic; I need the brand name medication,” is a common claim heard by many health care providers. Managed care organizations get numerous calls from doctors and patients requesting prior authorizations to approve brand name medications whilst there are generic alternatives available on formulary.… |
![]() |
Meet the new Beta 3 Agonist: Mirabegron (Myrbetriq®)...
August 1, 2012 - Clinical , Featured , In the News / Politics By: Steve P. Soman – Mirabegron (Mybetriq®), known also by the brand name Betanis®in Japan, is a new once daily oral drug. First in its class, it is a selective β(3)-adrenoceptor agonist that improves symptoms associated with over active bladder (OAB) such as urinary incontinence, urgency, and urinary frequency by enhancing storage function and relaxing… |
![]() |
DIA 2012: St. John’s Students Collaborate to Innovate...
August 1, 2012 - Events , Professional Advice / Opinions By: Michael Cronin, Pharm.D. Candidate c/o 2014 – The Drug Information Association (DIA) student chapter at St. John’s University College of Pharmacy and Health Sciences began in March of 2012 to provide a local forum for cultivating awareness of opportunities within the pharmaceutical industry among doctor of pharmacy and allied health professions candidates. Within two… |
![]() |
The Pathophysiology of Syndeham’s Chorea...
July 1, 2012 - Clinical , Featured By: Neal Shah, Co Editor-In-Chief – Dyskinesias are abnormal, involuntary movement disorders. Subsets of dyskinesias include choreas and atheosis. Chorea is irregular and sporadic contraction of muscles whereas athetosis involves a twisting and writhing of muscles. These two dyskinesias often occur together and are thus termed choreathetosis.1 Common conditions which feature choreatheosis are Huntington’s, and… |
![]() |
The Pathology of Pure Red Cell Aplasia...
July 1, 2012 - Clinical By: Neal Shah, Co Editor-In-Chief – Pure Red Cell Aplasia (PRCA), also known as erythroblastopenia, is characterized by a suppression of erythrocytes in the bone marrow. It is a peculiar oddity that the bone marrow’s progenitor cells still differentiate into white blood cells and platelets.1 PRCA has idiopathic, viral, auto-immune, and genetic etiologies. Diamond-Blackfan syndrome… |
![]() |
The Challenges of Pediatric Clinical Drug Trials and Dr...
June 1, 2012 - Clinical , Featured , Professional Advice / Opinions By: Shannon Tellier, Associate Student Editor – The disease burden in children outweighs the number of pediatric clinical drug trials currently being conducted. The lack of data in pediatrics leads to drugs being used off-label and without sufficient knowledge of doses, tolerability, and efficacy. In 1975, only 22% of products in the electronic Physicians’ Desk… |
![]() |
Effect of Intravenous Ondansetron on QT Interval Prolon...
June 1, 2012 - Clinical By: Raymond Wu, Pharm.D. Candidate c/o 2013 The 5-hydroxytryptamine type 3 (5HT3) antagonists (e.g. ondansetron [Zofran®]) are commonly used in the prevention and treatment of nausea and vomiting in the inpatient setting.1 Overall, ondansetron is a well-tolerated medication with few side effects.1 Constipation, dizziness, and headache are the most commonly reported side effects associated… |
![]() |
Risk versus Benefit: Prescription to Over the Counter M...
June 1, 2012 - Professional Advice / Opinions By: Maria A. Sorbera, Pharm.D. Candidate c/o 2013 – Maria Sorbera was the 2011-2012 President of the Rho Chi Beta Theta Chapter at the Arnold & Marie Schwartz College of Pharmacy at Long Island University (LIU). She is a strong advocate of networking with fellow pharmacists regardless of their area of expertise, as well… |
![]() |
Proton Pump Inhibitor Use and Complications...
June 1, 2012 - Clinical By: Lauren Kaveski, Pharm.D. Candidate c/o 2013 – We see proton pump inhibitors (PPIs) used in many medication regimens, but it is unknown whether the majority of patients receive these medications for appropriate durations or indications. For all labeled indications, other than Zollinger-Ellison Syndrome (a rare condition characterized by damaging gastrin hypersecretion and subsequent hydrochloric… |
![]() |
Rho Chi Post Interview with Dean Mangione...
May 1, 2012 - Featured , Professional Advice / Opinions By: Mohamed Dungersi & Mahdieh Danesh Yazdi, Associate Student Editors – Each month, the editors at the Rho Chi Post have the opportunity to interview one or more of our faculty members. This month, we had the tremendous opportunity to interview the dean of St. John’s University College of Pharmacy and Allied Health Professions, Dean… |
![]() |
Student Pharmacist Star of the Month: Michelle Pernice...
April 1, 2012 - Professional Advice / Opinions By: Marie Huang – Each month, the Rho Chi Post has the wonderful opportunity to sit down with an inspiring leader among the student pharmacists here at St. John’s University College of Pharmacy and Allied Health Professions – someone who is not afraid to stand apart from the crowd and can be the change he… |
![]() |
Sativex®: A Realistic Option for Advanced Cancer Pain?...
April 1, 2012 - Clinical , Featured , In the News / Politics By: Kathlynn Ferrer, Pharm.D. Candidate c/o 2013 – Nabiximols (Sativex®) is a buccal spray that has been approved for use in the UK, Spain, Germany, Denmark, New Zealand, and Canada. The active ingredients in this product are Tetrahydrocannabinol and Cannabidiol, two kinds of cannabinoids1. Cannabinoids are chemical compounds that stimulate cannabinoid receptors and are the… |
![]() |
Korlym® For Endogenous Cushing’s Syndrome...
April 1, 2012 - Clinical , In the News / Politics By: Alexandra Alleva, Pharm.D. Candidate c/o 2013 – On February 17, 2012, the US Food and Drug Administration (FDA) approved the first medication indicated specifically for patients with endogenous Cushing’s syndrome, a hormone disorder characterized by elevated blood levels of cortisol. Mifepristone (Korlym®) is for the treatment of glucose intolerance and Type 2 Diabetes Mellitus… |
![]() |
APhA Annuals 2012 in New Orleans...
April 1, 2012 - Events By: Nandini Puranprashad – This year we had an awesome turnout of 17 attendees representing the American Pharmacist Association Academy of Student Pharmacist (APhA-ASP) chapter of St. John’s University College of Pharmacy and Allied Health Professions at the APhA 2012 Annual Meeting & Exposition held in New Orleans from March 9th – 12th, 2012. New… |
![]() |
HMG-CoA Reductase Inhibitors And Memory Loss...
April 1, 2012 - Clinical , Featured By: Yufan (Frank) Liu, Pharm.D. Candidate c/o 2013 – Results of numerous epidemiological studies have indicated that having high serum cholesterol can lead to coronary heart disease (CHD). 1 More specifically having high LDL cholesterol puts patients at risk for angina and heart attack.2 To reduce this risk HMG-CoA reductase inhibitors, also known as statins,… |
![]() |
Counterfeit Prescription Medications: A Global Threat...
April 1, 2012 - Featured , In the News / Politics By: Lunbao (Jerry) Huang, Pharm.D. Candidate c/o 2013 – Counterfeit prescription medications are becoming a great concern for us. They have increased worldwide costs and endangered our public safety. Activities related to counterfeit drugs cost our healthcare system an estimated $75 billion in 2010. Many patients were seriously injured and died due to counterfeit medications.… |
![]() |
Drug Shortage Update: FDA Successfully Alleviates Chemo...
March 1, 2012 - In the News / Politics By: Mahdieh Danesh Yazdi – As previously reported, there is currently great concern in the medical community because of the growing number of drug shortages. Many of these are drugs that are critical to patient care, such as chemotherapy agents and antibiotics. Last October, President Obama issued an executive order in an attempt to curb… |
![]() |
Jentadueto Approved by FDA for Type 2 Diabetes Mellitus...
March 1, 2012 - Clinical , In the News / Politics By: Ebey P. Soman – The FDA recently approved a combination tablet of linagliptin with metformin hydrochloride (Jentadueto®) for the treatment of type 2 diabetes. Developed by Boehringer Ingelheim and Eli Lilly, the new combination tablet provides a twice-daily treatment option for healthcare providers looking for greater flexibility in treating diabetes. Prescribers may add a… |